Home LiteratureArticle Details
PMID: 8556325 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.

Brain research ·Vol. 695 ·No. 2 ·1995-10-16 ·Pages 151-7

Espino A, Cutillas B, Tortosa A, Ferrer I, Bartrons R, Ambrosio S

Abstract

Extracellular dopamine (DA) and its main cerebral metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were measured by bilateral striatal microdialysis in rats at different times (2, 7, 15 and 60 days) after unilateral administration into the right striatum of 1-methyl-4-phenylpyridinium ion (MPP+) or 6-hydroxydopamine (6-OHDA). In both cases the decrease in extracellular dopamine did not exceed 40% of control values. The response of DOPAC and HVA depended on the treatment: MPP+ caused a marked acute decrease in the dopamine metabolites but allowed a progressive recovery that was very evident after 60 days; 6-OHDA caused a progressive decrease in the dopamine metabolites throughout the two months of the study. Tyrosine hydroxylase immunostaining revealed severe neuronal loss in substantia nigra two months after striatal administration of 6-OHDA, whereas no significant neuronal loss was found at the same time after MPP+ administration. A bilateral challenge infusion of MPP+ through the microdialysis probe was used to assess the dopaminergic capacity of both striata: at all the times studied there was a sharp depletion of DA on the non-lesioned side; both MPP(+)- and 6-OHDA-treated striata were unresponsive after a short time (2 days); after 2 months the response in MPP(+)-lesioned rats was similar on both sides, whereas 6-OHDA-lesioned striata were still unresponsive to MPP+. In rats, then, the effects of MPP+ could be partly reversed whereas the effects of 6-OHDA were not. These results suggest that neurotoxins causing striatal dopamine loss may act through different mechanisms, which could be significant for the etiopathogenic development of Parkinson's disease.

MeSH Terms
1-Methyl-4-phenylpyridinium/administration & dosage,toxicity 3,4-Dihydroxyphenylacetic Acid/metabolism Animals Dopamine/metabolism Dopamine Agents/administration & dosage,toxicity Extracellular Space/drug effects,metabolism Homovanillic Acid/metabolism Immunohistochemistry Injections Male Microdialysis Neostriatum/drug effects,metabolism,pathology Oxidopamine/administration & dosage,toxicity Rats Rats, Sprague-Dawley Substantia Nigra/drug effects,pathology Sympatholytics/administration & dosage,toxicity
Chemicals
Dopamine Agents Sympatholytics 3,4-Dihydroxyphenylacetic Acid Oxidopamine 1-Methyl-4-phenylpyridinium Dopamine Homovanillic Acid
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Espino A
Unitat de Bioquímica, Universitat de Barcelona, Spain.
Cutillas B
Tortosa A
Ferrer I
Bartrons R
Ambrosio S
Article Info
Journal
Brain research
Abbr.
Brain Res
ISSN
0006-8993
Published
1995-10-16
Pages
151-7
Language
English
Region
Netherlands
NLM ID
0045503
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com